



an Open Access Journal by MDPI

## In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery

Guest Editors:

**Prof. Dr. Mei-Chin Lu**

Graduate Institute of Marine  
Biology, National Dong Hwa  
University, Hualien 944, Taiwan

**Dr. Mohamed El-Shazly**

Department of Pharmacognosy,  
Faculty of Pharmacy, Ain-Shams  
University, Organization of  
African Unity Street, Abassia,  
Cairo 11566, Egypt

**Dr. Kuei-Hung Lai**

Graduate Institute of  
Pharmacognosy, College of  
Pharmacy, Taipei Medical  
University, Taipei, Taiwan

Deadline for manuscript  
submissions:

**closed (10 June 2019)**

### Message from the Guest Editors

Despite three centuries of great scientific discoveries, the truth about oceans and their organisms remains elusive. Natural products, medicinal and synthetic chemists along with pharmacologists, biochemists, cell biologists and microbiologists united their forces to unleash hidden treasures of oceans and seas. New classes of secondary metabolites were discovered from marine organisms with an unprecedented spectrum of biological activities. Several compounds entered the drug pipeline and many others are in various stages of clinical trials. Scientists used all available biological assays to screen marine organism extracts and fractions to zoom in on the most important compounds.

This Special Issue of Marine Drugs entitled “In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery” focuses on presenting the most recent advances in biological assays applied for the discovery of marine secondary metabolites with potential biological activities. Full research papers and review articles reporting the applications of in vitro and in vivo assays to reveal biological activities of marine natural products, will be considered.



[mdpi.com/si/10942](https://mdpi.com/si/10942)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

## Contact Us

Marine Drugs Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
X@Marine\_Drugs